Objective: The aim of this study was to evaluate the effect of initial 2-day blood pressure management (BPM) after endovascular aneurysm repair (EVAR) for the incidence of subsequent type II endoleak (T2E) and shrinkage of abdominal aortic aneurysm (AAA) sac diameter. . Starting from 2013, the mean blood pressure of 76 participating patients (treatment group) was maintained at 75 to 90 mm Hg for the initial 48 hours after EVAR. The incidence of T2E at 7 days and AAA sac diameter 12 months after EVAR were evaluated using computed tomography scanning. The results so obtained were then compared with those of the control group composed of 60 consecutive patients who underwent EVAR before 2013.
Endovascular aneurysm repair (EVAR) is considered a less invasive treatment alternative to open aneurysm repair for abdominal aortic aneurysm (AAA). Randomized trials have demonstrated favorable short-term results, such as reduced 30-day mortality, compared with surgical repair.
1,2 However, unexpected negative outcomes have been recognized during follow-up, especially the occurrence of various endoleaks. Endoleak is defined as continued perfusion of the aneurysm sac despite endograft placement and is generally classified into four types. 3 The presence of type I and type III endoleaks is associated with high-pressure leaks and generally requires secondary interventions because of the high possibility of aneurysm rupture. On the other hand, type II endoleak (T2E) is caused by backflow of collateral arteries into the aneurysm sac, and it is thought to be a low-pressure leak. 4, 5 Secondary intervention for T2E has been controversial because some experts consider that T2Es have no immediate adverse effects, whereas others have implied that T2Es cause late ruptures. [6] [7] [8] According to a previous high-volume report, approximately 20% of patients required secondary intervention during the mean follow-up of 3 years after EVAR. 9 The leading reason for secondary intervention was AAA sac enlargement by T2E up to 40%, followed by type I endoleak of 15%. Considering the report of late rupture due to T2E, the management of T2E is a major concern in the era Japan (e-mail: miura-sh@keijinkai.or.jp).
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Copyright of EVAR. Conventionally, most T2Es have been managed by transcatheter embolization as a less invasive treatment. However, a secondary intervention for T2E is technically demanding and has a reportedly low successful rate. 10 Considering these factors, the prevention of T2E
should be more important instead of secondary intervention. Based on the observation of increased T2E blood flow on digital subtraction angiography at the time of a high systemic blood pressure during EVAR, we hypothesized that reducing blood pressure might reduce the incidence of T2E. Although the incidence of T2E seems to be changing in the follow-up period, secondary intervention for persistent T2E has been performed >1 year after EVAR. The appropriate timing to detect persistent T2E that may cause AAA sac enlargement is not entirely understood. However, it has been reported that T2E detected by completion angiography at the time of EVAR has no relationship with aneurysm shrinkage. On the other hand, T2E at 7 days and 6 months after EVAR was associated with a lack of shrinkage. 11 Based on these findings, even 7 days after EVAR may be appropriate to check for the existence of T2E. Reducing the incidence of T2E at 7 days after EVAR may improve long-term outcomes. In this study, we investigate the relationship between post-EVAR blood pressure management (BPM) and the incidence of T2E at 7 days after EVAR. We also report the size of AAA sac at 1 year after EVAR according to the use of BPM.
METHODS
Medical records of all patients who underwent EVAR for infrarenal AAA between July 2008 and July 2014 at our institute were reviewed retrospectively. From January 2013, we attempted to maintain the mean blood pressure of the participating patients, composing the treatment group, at 75 to 90 mm Hg for the initial 48 hours after EVAR. All procedures of EVAR were performed under general anesthesia without withdrawal of preoperative antiplatelet and antihypertensive medicines. After completion of EVAR, all patients were extubated in the operating room and transported to the intensive care unit (ICU). Blood pressure was controlled by continuous intravenous administration of nicardipine hydrochloride under radial artery line monitoring. Although the patients took antihypertensive medicines on the morning of EVAR, preoperatively prescribed oral medicines were temporarily suspended in the ICU, considering possible inspiration trouble secondary to general anesthesia for the elderly. On the second day after operation, patients were transferred to the general ward, and arterial pressure was cuff monitored every 6 hours. The pressure was maintained by resuming the administration of preoperative oral antihypertensive medicines in addition to intravenous injection of nicardipine hydrochloride. Nicardipine hydrochloride was stopped on the third postoperative day, and blood pressure was managed in the same way as it was before the operation. On the other hand, from July 2008 to December 2012, the patients composing the control group were directly transported to the general ward, and short-acting calcium channel blocker medicine was given when their blood pressure was extraordinarily higher than usual; preoperative antihypertensive medicine was resumed on the second postoperative day.
All the patients underwent contrast-enhanced computed tomography (CT) scanning of early and delayed arterial phases at 7 days and contrastenhanced or noncontrast-enhanced CT at 12 months after EVAR. During the period from discharge to 1-year follow-up, the patients were followed up by noncontrast-enhanced CT when their AAA size was stable. Two or more cardiovascular surgeons reviewed all images of CT scans. In the case that contrast-enhanced CT scanning could not distinguish T2E from other types of endoleaks, the type of endoleak was identified by ultrasound. Exclusion criteria of this study were any patients undergoing emergent EVAR; patients with type I or type III endoleak, severe renal dysfunction, hemodialysis, occlusion of bilateral internal iliac arteries, severe arteriosclerosis obliterans, or surgical history of thoracic aortic aneurysm repair; patients who had use of specific stent grafts (Zenith [Cook Medical, Bloomington, Ind], Talent [Medtronic Vascular, Santa Rosa, Calif], and Aorfix [Lombard Medical, Irvine, Calif] were used only in one group); and patients for whom sufficient data could not be obtained from electronic records. Exclusion criteria were determined to prevent possible complications secondary to reduced blood pressure, such as ischemic colitis, spinal cord ischemia, leg ischemia, and stent graft leg thrombo-occlusion. Some patients who could not be kept in the targeted blood pressure range were excluded. The incidence of T2E at 7 days and AAA sac diameter at 12 months were compared with those of the control group patients. The analyzed variables with respect to their possible effect on the incidence of T2E at 7 days and AAA sac shrinkage We did not obtain individual consents for postoperative BPM from all the enrolled patients or their families before EVAR procedures because our postoperative antihypertensive therapy was done per usual medical practice. This clinical study was performed with the approval of the hospital ethics committee.
ARTICLE HIGHLIGHTS
Statistical analysis. Continuous variables and categorical variables between groups were compared using t-test and Fisher exact test, respectively. Categorical analysis with stratification was performed using Fisher exact test. Multivariate regression analysis for factors associated with T2E and AAA sac diameter was performed using the logistic regression and general linear model, respectively. P values < .05 were considered to be statistically significant. All statistical analyses were performed using JMP 10.0 software (SAS Institute, Cary, NC).
RESULTS
Between July 2008 and July 2014, 174 patients underwent EVAR for the treatment of AAA with use of a commercial device. Thirty-eight patients were excluded from the evaluation per the exclusion criteria. The remaining 136 patients (122 men, 14 women; mean age, 76 years [range, 56-93 years]) were enrolled in this study. The 76 patients (56%) whose mean blood pressure was maintained at 75 to 90 mm Hg for the initial 48 hours after EVAR (the treatment group) and the 60 patients (44%) who received normal postoperative management (NPM, the control group) were evaluated 7 days and 12 months after EVAR using CT scanning. During the follow-up period, there were no patients with AAA rupture or who required additional secondary intervention to treat T2Es. Table I demonstrates the demographics of the 136 enrolled patients. The following factors did not have any significant difference between the treatment group and the control group: age, gender, and concomitant diseases. Regarding preoperative medical therapy, the patients were divided into five categories: patients who received neither antiplatelet nor anticoagulant therapy; patients who received single antiplatelet therapy; patients who received multiagent antiplatelet therapy, such as clopidogrel bisulfate, ticlopidine hydrochloride, or cilostazol as well as aspirin; patients who received anticoagulant therapy including warfarin potassium; and patients who received both antiplatelet and anticoagulant therapy. However, no significant difference was observed between the two groups regardless of the patients' categories. Table II describes the anatomic characteristics of the preoperative aneurysm sac in all the patients. There were statistically significant differences in the rate of aneurysm with neck thrombus and one pair of patent lumbar arteries (LAs) between the two groups. However, these anatomic spectrums were not considered risk factors responsible for the increase in T2E at 7 days in multivariate analysis (data presented later). General operative data showed no significant difference with respect to the type of endografts and additional procedures (proximal cuff, distal iliac extension, internal iliac artery or inferior mesenteric artery [IMA] coiling) between the two groups. The blood pressure values at 3, 12, 24, and 48 hours after EVAR in the treatment group were significantly lower than those in the control group, although there was no difference at 6 months in the outpatient clinic between the two groups (Table III) . The univariate analysis revealed that the incidence of T2E at 7 days (19%) in the treatment group was significantly less than that of T2E (40%) in the control group (P ¼ .013), and the percentage of shrunken AAA diameter in the treatment group was statistically higher than in the control group (9.9% and 4.5%; P < .001). In multivariate analysis (Table IV) , BPM (Table V) , it was found that the usage of Excluder in the treatment group significantly improved the incidence of T2E from 80% to 23% (P ¼ .001), and the use of Powerlink in the treatment group also improved the incidence of T2E from 42% to 8% (P ¼ .05). However, the use of Endurant showed no significant effect. On multiple regression analysis (Table VI) , BPM was identified as an independent factor for the shrinkage of AAA sac diameter at 12 months (size difference of À2.91 mm; 95% CI, À4.91 to 0.92; P ¼ .005), and the perioperative use of either antiplatelet medicine or warfarin did not tend to reduce the size of aneurysm sac (size difference of þ1.91 mm; 95% CI, À0.10 to 3.91; P ¼ .06). Fig 1  reveals that AAA sac shrinkage at 12 months after EVAR was influenced by BPM and perioperative medication of either antiplatelet medicine or warfarin. AAA sac diameter in patients who received BPM even with perioperative medications significantly decreased compared with those patients who received NPM with perioperative medications (P ¼ .025). This shows that BPM had exceeded the effect of perioperative medications and facilitated the shrinkage of AAA sac volume. Fig 2 shows AAA sac shrinkage at 12 months after EVAR in the 15 patients who received BPM with T2E, 24 patients who received BPM without T2E, 61 patients who received NPM with T2E, and 36 patients who received NPM without T2E. Although AAA sac shrinkage was obtained in patients who received BPM regardless of the presence of T2E, sac diameter in patients who received BPM without T2E had a mean decrease of 5.9 mm more than in other patients.
DISCUSSION
T2E had been considered to be benign; however, Schlosser et al 12 presented a review of 270 cases of AAA rupture after EVAR, and AAA rupture associated with Data are presented as the mean 6 standard deviation or number (%). Reverse taper was defined as a proximal neck with an aortic diameter that increases by >4 mm over the course of 10 mm below the renal arteries. Neck thrombus was defined as a proximal neck with apparent thrombus >40%.
T2E occurred in 23 of 235 cases. A current consensus is that the treatment for T2E should be considered when aneurysm sac enlargement continues. Secondary interventions for T2E, including conversion to open surgical repair, arterial embolization, and laparoscopic clipping of IMA or LAs, have been performed to prevent continued aneurysm sac enlargement and to reduce the risk of aneurysm rupture. 13 However, the optimal timing and long-term outcomes of secondary interventions for T2E are still unclear. Solis et al 10 reported that the failure rate of secondary interventions for T2E was >60%, and multiple accesses and attempts were required over time. Therefore, the prevention of T2E might be more important than the treatment of T2E. We hypothesized that reduced BPM might reduce the retrograde blood flow into AAA through the IMA or LAs, which resulted in lower incidence of T2E. We also hypothesized that the acute postoperative phase when patients are generally thought to be in a hypercoagulant T2Es generally occur in 12% to 30% of patients undergoing EVAR. Compared with other reports, the incidence of T2E might be higher in our study. As possible reasons, several factors might be raised. Warfarin or antiplatelet medicine was preoperatively and postoperatively prescribed for the cases of >60%. There might be a racial difference regarding coagulopathy. T2E was diagnosed when the LA was patent and reached the edge of the AAA by contrast-enhanced CT even if there was no obvious contrast-enhanced space in the AAA because it was unknown whether the size of the contrastenhanced space in the AAA was connected to enlargement of the AAA. We believed that patent LAs have possible harmful effects, the same as so-called T2E in terms of endotension. 16 As a method to detect T2E, CT is thought to be more sensitive than duplex ultrasound. Therefore, our diagnosis criteria of T2E might include broader cases. To compare the incidence of T2E in the two groups, the numbers of possible arterial sources should be even. In this study, a percentage of the cases with patent IMA was slightly higher in the control group (61% in the treatment group vs 76% in the control group). However, considering that the number of patent branching arteries from the AAA was 3.32 in the treatment group and 3.18 in the control group, we believed that the number of possible sources of T2E was the same in both groups. Many reports suggest that 60% to 80% of T2Es disappear spontaneously within 6 months of EVAR. 17 
Such
T2Es are known as transient T2E, which gradually increases and peaks in the first 6 months after EVAR. Jones et al 8 reported that persistent T2E that remains for >6 months after EVAR poses a risk for aneurysm sac enlargement. Furthermore, Aoki et al 11 presented that T2E detected at 7 days and 6 months after EVAR was correlated with a lack of shrinkage. Based on this finding and the unique medical insurance system in our country that allows most patients to stay in the hospital longer than 1 week after EVAR, the first CT scan with contrast enhancement has been carried out on the seventh day after EVAR to evaluate T2E. In our study, multivariate analysis showed that BPM significantly reduces the incidence of T2E at 7 days, and it was also identified as an independent factor for shrinkage of AAA sac diameter at 12 months. In addition, we found that BPM might decrease the mean diameter of the AAA sac at 12 months regardless of the presence of T2E at 7 days after EVAR. Among the 15 patients with T2E at 7 days after BPM, T2E had disappeared after 6 months in the 10 patients whose AAA sac was not enlarged at 12 months. On the other hand, T2E remained even after 6 months as persistent T2E in the remaining five patients whose AAA sac was enlarged at 12 months. We recognized that even though T2E remained after 7 days despite BPM, AAA sac diameter might decrease if T2E had disappeared within 6 months after EVAR.
This study revealed that the effects of BPM varied according to the type of endograft used. The use of Excluder or Powerlink followed by BPM significantly improved the incidence of T2E more than the use of Endurant. We assumed that one of the reasons might be the differences in the endograft structures. Based on our data (not shown) of intraoperative measurement of AAA sac pressure after endograft placement, the Excluder device, which does not cause type IV endoleak, greatly decreases intrasac pressure compared with Endurant, which frequently causes type IV endoleak. 18 On the other hand, the Endurant device might generate a lower pressure gradient with the presence of type IV endoleak. This possible mechanism after the deployment of Endurant might be more powerful in reducing the incidence of T2E rather than the effect of BPM. Regarding a possible bias of stent graft generation, each of the three stent grafts had the same generation in both groups.
As Aoki et al and Bobadilla et al reported, 11, 19 the preoperative use of either antiplatelet medicine or warfarin posed a risk of increasing the incidence of T2E, and the patients requiring these medications for other indications after EVAR are at increased risk for secondary interventions and persistent sac expansion. In this study, 84 patients (64%) received either antiplatelet or warfarin therapy because of a history of coronary artery disease, cerebral vessel disease, cardiac prosthetic valve replacement, and chronic atrial fibrillation. However, BPM was an effective therapy to facilitate AAA sac shrinkage at 12 months regardless of the presence of this risk factor. Although statistically not significant, the number of patients who were prescribed both warfarin and antiplatelet medicine was higher in the control group. Considering a high incidence of T2E in cases with the use of warfarin or antiplatelet medicine, an influence of this factor against T2E needs to be evaluated using a much larger cohort. There are several possible limitations in this study. First, this study was retrospective. The number of enrolled patients was small. Enhanced CT scanning was solely relied on for the evaluation of endoleaks; this could not identify all T2Es because the time phases of CT scanning were possibly different in each patient. Furthermore, precise postoperative blood pressure data of the control group could not be obtained because of this being a retrospective study. In addition, the diameters of the IMA and LAs branching from the AAA sac, which might be associated with the incidence of T2E, were obviously different in each patient. Because of the small-caliber vessels measured by CT scanning, this factor was excluded from analysis of variables. The outcomes of this study might have a device selection bias because the selection of endograft was decided by anatomic figures of the aneurysms.
Finally, adopting this kind of postoperative management in the current clinical setting might raise a concern about medical cost. Although we used the ICU, considering patients' safety, we believe that the method of reducing blood pressure in the superacute phase can be modified even after being discharged to home, considering the general rule of each country's health care system. We suppose that this study could show only the usefulness of BPM in the superacute phase but did not reveal the appropriate method and the preferable level of blood pressure.
CONCLUSIONS
To our knowledge, this is the first study to evaluate the efficiency of postoperative BPM after EVAR. The initial 2-day postoperative BPM might lead to shrinkage of aneurysm sac diameter by reducing the incidence of T2E. More detailed studies on this topic with a larger number of patients are warranted. Dr Miura and colleagues have studied whether tight blood pressure (BP) control with intravenous medication after elective endovascular aneurysm repair (EVAR) might decrease type II endoleak (T2E). They found decreased incidence of T2E and enhanced sac shrinkage at 1 year both in those in whom no T2E developed and even when T2E persisted. They placed all patients in the intensive care unit after elective EVAR. This type of perioperative care is not standard, as most patients undergoing EVAR are not placed in critical care or step-down units unless they develop complications. The movement has been toward shorter hospital stays, with studies looking at same-day discharge. 1 The authors hypothesized that lower BP postoperatively, a time when the patient is somewhat hypercoagulable, leads to thrombosis of the small branches, thereby averting T2E. The concept of preventing T2E at the time of initial procedure is not new, as several groups have assessed models to predict high risk for T2E 2,3 using anatomic features, number and size of patent feeding arteries, and other factors. These groups have then looked at pre-emptive coil embolization to prevent T2Es. [2] [3] [4] Clearly, if we can decrease the need for secondary procedures in EVAR patients, that would be beneficial. The question becomes the cost-benefit ratio. In today's current economic environment, procedures or activities that are not standard of care and are costly are closely scrutinized by hospital administrators. Not every patient will develop a T2E and therefore would not need enhanced BP control to avert this potential problem. The length of time for which tight BP control might be needed is also unclear. Unfortunately, the authors do not have data as to BP control once the patient was discharged. The bigger issue becomes whether BP can be controlled in less expensive settings or by less invasive methods. To make the concept of tight BP control as a method of decreasing T2E feasible financially, these issues would need further exploration before widespread adoption would be considered. Certainly, if tight BP control is as effective as pre-emptive sac embolization, BP control would likely be less expensive, as coils are costly, and would also not interfere with future imaging of the aneurysm sac, nor would it prevent sac shrinkage.
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